Drug
Gilteritinib clinical trials
Also written ASP2215 and XOSPATA®.
- studies test it
- 43
- open now
- 21
- in phase 3
- 10
- first study started
- 2014
Keep track of what changes. Save the gilteritinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
43 studies that test it; most in 2024 (8)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 4 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 5 |
| 2020 | 3 |
| 2021 | 3 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 8 |
| 2025 | 3 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 24
- Phase 2
- 18
- Phase 3
- 10
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 20 · Other 23
Astellas Pharma Global Development, Inc. (13) · Institute of Hematology & Blood Diseases Hospital, China (4) · M.D. Anderson Cancer Center (4) · Astellas Pharma Inc (3) · Oryzon Genomics S.A. (1) · Stichting Hemato-Oncologie voor Volwassenen Nederland (1) · PrECOG, LLC. (1) · AbbVie (1)
Often tested with
Tested in the same studies.
Venetoclax (13) · Azacitidine (10) · Cytarabine (6) · Daunorubicin (4) · Ivosidenib (4) · Enasidenib (3) · CPX-351 (3) · Mitoxantrone (3)
Studies
Open first, then newest update. How each study uses gilteritinib is read from its arms, and is right about nine times in ten.
Testing it · 43
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05564390Written as Gilteritinib
- A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)RecruitingPhase 1Astellas Pharma Global Development, Inc.NCT07140016Written as gilteritinib
- Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in RemissionRecruitingPhase 1M.D. Anderson Cancer CenterNCT05010772Written as Gilteritinib
- Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative NeoplasmRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT04140487Written as Gilteritinib
- A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid LeukemiaRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06235801Written as Gilteritinib
- A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 MutationsRecruitingPhase 3Children's Oncology GroupNCT04293562Written as Gilteritinib Fumarate
- ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT05010122Written as Gilteritinib
- Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaRecruitingPhase 2/3Beat AML, LLCNCT03013998Written as Gilteritinib (BAML-16-001-S8 Group 1)
- MRD-positive AML Clinical StudyRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT07131059Written as Gilteritinib
- Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid LeukemiaRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT06265545Written as Gilteritinib
- Gilteritinib for the Treatment of ALK NSCLCRecruitingPhase 1University of Michigan Rogel Cancer CenterNCT06225427Written as Gilteritinib
- Immunological Impact of a Post Cell Therapy Treatment With FLT3 InhibitorsNot yet recruitingNot applicableCentre Hospitalier Universitaire de NiceNCT06992934Written as Gilteritinib
- SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 MutationRecruitingPhase 1Uma BorateNCT06222580Written as Gilteritinib
- The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 MutationRecruitingPhase 1/2Institute of Hematology & Blood Diseases Hospital, ChinaNCT06561880Written as Gilteritinib
- VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AMLNot yet recruitingPhase 3Institute of Hematology & Blood Diseases Hospital, ChinaNCT07407140Written as Gilteritinib + Azacitidine + Venetoclax
- MRD-guided Maintenance Post-HCT: Gilteritini vs SorafenibRecruitingPhase 3The First Affiliated Hospital of Soochow UniversityNCT07463651Written as Gilteritinib
- FLT3-ITD Targeted Therapy in Fit AML PatientsNot yet recruitingPhase 2/3European Organisation for Research and Treatment of Cancer - EORTCNCT07425808Written as Gilteritinib
- Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AMLRecruitingPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT05024552Written as Gilteritinib
- Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive TreatmentRecruitingPhase 2Technische Universität DresdenNCT06696183Written as Gilteritinib (GILT)
- Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid LeukemiaRecruitingPhase 2French Innovative Leukemia OrganisationNCT06022003Written as Xospata
See all 43 studies that test gilteritinib →
Given in every arm · 15 — gilteritinib is usual care beside what is tested
- Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT06317649Written as Gilteritinib
- Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway MutationsRecruitingPhase 2M.D. Anderson Cancer CenterNCT07032727Written as Gilteritinib
- A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid LeukemiaRecruitingPhase 2St. Jude Children's Research HospitalNCT05955261Written as Gilteritinib
- Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid LeukemiaRecruitingPhase 1Kura Oncology, Inc.NCT06001788Written as Gilteritinib
- Study of SA+X in the Treatment of Newly Diagnosed AMLRecruitingPhase 2Ruijin HospitalNCT07548710Written as Gilteritinib
- Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid LeukemiaRecruitingPhase 2M.D. Anderson Cancer CenterNCT02115295Written as Gilteritinib
- A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)RecruitingPhase 1/2Sumitomo Pharma America, Inc.NCT04988555Written as Gilteritinib
- Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AMLRecruitingPhase 2Children's Hospital of Soochow UniversityNCT06221683Written as Gilteritinib
- A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)Active, not recruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT05756777Written as Gilteritinib
- Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedPhase 1/2Astellas Pharma Global Development, Inc.NCT02014558Written as Gilteritinib
- A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)TerminatedPhase 1/2Astellas Pharma Global Development, Inc.NCT02495233Written as Gilteritinib
- A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedPhase 1Astellas Pharma Global Development, Inc.NCT02236013Written as Gilteritinib
- Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AMLActive, not recruitingPhase 3Chen SuningNCT05177731Written as Gilteritinib
- A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic MalignanciesWithdrawnPhase 1/2Erasca, Inc.NCT05279859Written as Gilteritinib
- Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell TransplantationWithdrawnPhase 1City of Hope Medical CenterNCT04655391Written as Gilteritinib Fumarate
Codes
What other systems call gilteritinib · ClinicalTrials.gg INT000493
- MeSH (NLM) C000609080gilteritinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 66D92MGC8MGILTERITINIBConfirmed FDA, NLM, Wikidata
- RxNorm 2105806Confirmed FDA, Wikidata
- Wikidata Q27077802gilteritinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C116722GilteritinibOne source FDA
- DrugBank DB12141One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000609080 | gilteritinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 66D92MGC8M | GILTERITINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2105806 | — | Confirmed FDA, Wikidata |
| Wikidata | Q27077802 | gilteritinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C116722 | Gilteritinib | One source FDA |
| DrugBank | DB12141 | — | One source Wikidata |
Also registered as gilteritinib fumarate (UNII 5RZZ0Z1GJT · RxNorm 2105823).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.